Abstract
Systemic administration of voriconazole, a novel anti-fungal agent, is associated with adverse effects including visual disturbances and hepatic abnormalities. The purpose of this study was to improve the aqueous solubility of voriconazole using 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) and to study the effect of addition of viscosity modifiers to these solutions. Statistical analysis was done by one-way analysis of variance followed by Dunnett's test. The phase solubility studies indicated that voriconazole solubility increased with increase in HP-β-CD concentration. Using a combination of chitosan 0.2%, BAK 0.01% and EDTA 0.01% in voriconazole- HP-β-CD based aqueous drops (1.5%, pH 7.0), a 3.9 times and 5.4 times higher Papp was obtained than with formulation without chitosan and control formulation (without chitosan and preservative), respectively. Thus, it could be concluded voriconazole aqueous drops formulated using HP-β-CD can be used topically for the treatment of fungal keratitis and the addition of chitosan to the voriconazole aqueous drops can produce significantly higher permeation.
Keywords: Chitosan, Fungal keratitis, HP-β-CD, Phase solubility, Transcorneal permeation, Voriconazole.
Current Drug Delivery
Title:Design and Evaluation of HP-β-CD Based Voriconazole Formulations for Ocular Drug Delivery
Volume: 11 Issue: 2
Author(s): Priyanka Pahuja, Heena Kashyap and Pravin Pawar
Affiliation:
Keywords: Chitosan, Fungal keratitis, HP-β-CD, Phase solubility, Transcorneal permeation, Voriconazole.
Abstract: Systemic administration of voriconazole, a novel anti-fungal agent, is associated with adverse effects including visual disturbances and hepatic abnormalities. The purpose of this study was to improve the aqueous solubility of voriconazole using 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) and to study the effect of addition of viscosity modifiers to these solutions. Statistical analysis was done by one-way analysis of variance followed by Dunnett's test. The phase solubility studies indicated that voriconazole solubility increased with increase in HP-β-CD concentration. Using a combination of chitosan 0.2%, BAK 0.01% and EDTA 0.01% in voriconazole- HP-β-CD based aqueous drops (1.5%, pH 7.0), a 3.9 times and 5.4 times higher Papp was obtained than with formulation without chitosan and control formulation (without chitosan and preservative), respectively. Thus, it could be concluded voriconazole aqueous drops formulated using HP-β-CD can be used topically for the treatment of fungal keratitis and the addition of chitosan to the voriconazole aqueous drops can produce significantly higher permeation.
Export Options
About this article
Cite this article as:
Pahuja Priyanka, Kashyap Heena and Pawar Pravin, Design and Evaluation of HP-β-CD Based Voriconazole Formulations for Ocular Drug Delivery, Current Drug Delivery 2014; 11 (2) . https://dx.doi.org/10.2174/1567201810666131224105205
DOI https://dx.doi.org/10.2174/1567201810666131224105205 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Peripartum Cardiomyopathy: Moving Towards a More Central Role of Genetics
Current Cardiology Reviews Autoantibodies for Cardiac Channels and Sudden Cardiac Death and its Relationship to Autoimmune Disorders
Current Cardiology Reviews Prognostic Implications of Genetics in Cardiovascular Disease
Current Pharmacogenomics Are Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?
Current Pharmaceutical Design Anti-Inflammatory Therapy in Uveitis
Recent Patents on Inflammation & Allergy Drug Discovery Persistence of Trypanosoma cruzi in Experimental Chagasic Cardiomyopathy
Anti-Infective Agents Takotsubo Syndrome: Clinical Manifestations, Etiology and Pathogenesis
Current Cardiology Reviews Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk
Current Vascular Pharmacology Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy
Current Pharmaceutical Design Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets By Discontinuing Beta-Blockers Before an Exercise Test, We may Precipitate a Rebound Phenomenon
Current Vascular Pharmacology Pro- and Anti-Arrhythmic Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry New Advances in the Field of Calcium Channel Antagonists: Cardiovascular Effects and Structure-Activity Relationships
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Potential Treatment of Cardiac Hypertrophy and Heart Failure by Inhibiting the Sarcolemmal Binding of Phospholipase Cβ1b
Current Drug Targets Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Heart Transplantation in Biventricular Congenital Heart Disease: Indications, Techniques, and Outcomes
Current Cardiology Reviews Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry A Timely Review of State-of-the-Art Chronopharmaceuticals Synchronized with Biological Rhythms
Current Drug Delivery Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design